Igl India Transplantation Solutions Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 31-10-2024
- Paid Up Capital ₹ 1.63 Cr
as on 31-10-2024
- Company Age 4 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -20.41%
(FY 2023)
- Profit -50.06%
(FY 2023)
- Ebitda -57.84%
(FY 2023)
- Net Worth -2.28%
(FY 2023)
- Total Assets -2.60%
(FY 2023)
About Igl India Transplantation Solutions
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.63 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkatram Bakthavatchalam, Daniel Humbert, and Alexandre Lopez serve as directors at the Company.
- CIN/LLPIN
U74999TN2020FTC134360
- Company No.
134360
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
11 Feb 2020
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Igl India Transplantation Solutions?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkatram Bakthavatchalam  | Director | 11-Feb-2020 | Current |
Daniel Humbert  | Director | 11-Feb-2020 | Current |
| Alexandre Lopez | Director | Current |
Financial Performance of Igl India Transplantation Solutions.
Igl India Transplantation Solutions Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 20.41% decrease. The company also saw a substantial fall in profitability, with a 50.06% decrease in profit. The company's net worth dipped by a decrease of 2.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Igl India Transplantation Solutions?
Unlock access to Igl India Transplantation Solutions's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Aravindha Medical Innovations LlpActive 3 years 5 months
Venkatram Bakthavatchalam is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Igl India Transplantation Solutions?
Unlock and access historical data on people associated with Igl India Transplantation Solutions, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Igl India Transplantation Solutions, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Igl India Transplantation Solutions's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
